On July 1, 2026, five insiders at Oruka Therapeutics, Inc. (ORKA) executed significant share sales, collectively divesting approximately $1.50 billion worth of stock. Among the sellers were Peter Evan Harwin, Healthcare Fund Ii L.P. Fairmount, Funds Management Llc Fairmount, Tomas Kiselak, and Healthcare Co-Invest Iii L.P. Fairmount, each selling 3,553,410 shares at a price of $84.43 per share.
These transactions represent substantial sales from individuals and entities holding director and 10% owner positions within the company. While insider selling can stem from various personal financial strategies, such as portfolio diversification or the need for liquidity, a coordinated sale of this magnitude by multiple key insiders may draw investor attention.
The total value of the disclosed sales reached $1.50 billion, with each of the five identified insiders selling shares valued at approximately $300 million. The timing and scale of these divestitures occurred amidst broader market conditions, and their implications for Oruka Therapeutics' future valuation are a subject of ongoing market observation.